SAN DIEGO, January 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today posted a "Frequently Asked Questions" document in the "Investors" section of its website regarding its recent dividend to Sorrento shareholders of common shares of Scilex Holding Company owned by Sorrento.
The FAQ addresses questions about dividend details, including record date, payment date, dividend rate, distribution of Scilex common stock, how Sorrento shareholders can obtain certain dividend information, CUSIP information for common stock and transfer of Scilex restrictions on dividend shares, as well as issues relating to dividend issues that may arise in relation to short positions in Sorrento common stock.
FAQs and related exposures are included in this press release and can also be found here.
COMMON QUESTIONS
IN RELATION TO THE DIVIDEND ON COMMON SHARES OF SCILEX HOLDING COMPANY OF SORRENTO THERAPEUTICS, INC.
P:What is the dividend on Scilex common stock?
A: As of December 30, 2022, Sorrento Therapeutics, Inc. (Sorrento) announced that its board of directors declared a stock dividend (dividing) composed of a total of 76,000,000 shares (dividend stock) of common shares of Scilex Holding Company held by Sorrento to the registered holders of:
- Sorrento Common Stock (Register of Common Owners) at the close of business on the Record Date, and
- certain warrants to purchase shares of Sorrento common stock (which are or may be entitled to participate in the Dividend pursuant to the terms of their respective warrants) (Search warrant holdersand together with the Common Record Holders,record holders).
The Dividend would be distributed pro rata to such holders in accordance with each holder's percentage ownership of Sorrento common shares (assuming full exercise of all outstanding warrants to purchase Sorrento common shares) as of the Record Date, as stated in the records. of the transfer agent of Sorrento (with respect to Common Registration Holders) and Sorrento (with respect to Registration Security Holders) on such date.
No fractional shares will be issued in connection with the Dividend and Record Holders who would otherwise be entitled to receive fractional shares of Scilex common stock are entitled to receive cash (without interest or deductions) in lieu of such fractional shares for an amount equal to the product obtained by multiplying (a) $5.87 (representing the closing price of Scilex common shares on the Record Date), by (b) the fraction of one Scilex common share that said registration would be entitled to receive as a Dividend with respect to the common shares of Sorrento held by such Registration Holder (after adding all fractional shares that could be issued to such Registration Holder in connection with the Dividend) (pay instead of cash).
P:What was the dividend record date?
A: The record date for determining Sorrento shareholders who are entitled to receive stock dividends was January 9, 2023.
P:What was the bonus payment date?
A: The payment date of the Dividend in Shares was January 19, 2023 (Payday).
P:What was the dividend rate?
A: The dividend rate is 0.1410127 of a Scilex common share for each Sorrento common share held (or underlying the relevant warrants) by Record Holders at close of business on the Record Date.
P:Will I receive stock dividends?
A: If you are a Registered Common Holder, which means you owned Sorrento common stock at the time of close of business on the Record Date, you are entitled to receive dividend shares.
P:How do I know if I am an ordinary registration holder?
AN:Registered Shareholder: Shares registered in your name
If, at the close of business on January 9, 2023, your shares of Sorrento common stock were registered directly in your name with Sorrento's transfer agent, Pacific Stock Transfer Company (pacific time), then you are the registered shareholder of those shares and a registered common owner.
Beneficial Owner: Shares registered in the name of a broker, bank or other agent
If, at the close of business on January 9, 2023, your Sorrento common stock is in your possession,not in your name, but in an account with a brokerage, bank, dealer or other similar organization, then you are the beneficial owner of the shares held in "name of the street" and the organization holding your account is considered the shareholder of record, or the common Register of holder, for the purposes of the Dividend.As a beneficial owner, you have the right to tell your broker, bank or other agent which share of the dividend shares you are the beneficial owner and how this is reflected in your account.
P:What information and documentation was distributed to common record holders in connection with the dividend?
AN:Registered Shareholder: Shares registered in your name
If, at the close of business on January 9, 2023, your Sorrento common stock was registered directly in your name with Sorrento's transfer agent, PST, PST will mail the Disclosure Statement to your PST registered address.A copy of the Information Statement is attached to these FAQs asAppendix A.
Furthermore, on January 19, 2023, Scilex's transfer agent, Continental Stock Transfer & Trust Company (CST), distributed to you as an Ordinary Record Holder (i) your pro rata share of dividend shares based on the dividend rate and (ii) a cash payment in lieu of payment if you were entitled to receive Scilex Common Shares Fractional Bonds.
Dividend shares are evidenced by a DRS transaction confirmation/book entry (Dividend Confirmation), whose dividend confirmation has been sent to your registered address with the Sorrento transfer agent, PST. Consequently, you are now a registered shareholder of your dividend shares and your shares are registered directly in your name with Scilex's transfer agent, CST. If you were entitled to a payment in lieu of cash, a check for that payment was also sent to your PST registered address.
Beneficial Owner: Shares registered in the name of a broker, bank or other agent
If, at the close of business on January 9, 2023, your Sorrento common stock is in your possession,not in your name, but in an account with a brokerage, bank, dealer or other similar organization, then you are the beneficial owner of the shares held in "name of the street" and the organization holding your account is considered the shareholder of record, or the common Register of holder, for the purposes of the Dividend.
As a Common Holder of Registration, your broker or other agent must have received the Statement of Information directly from PST. A copy of the Information Statement is attached to these FAQs asAttachment.
As a beneficial owner, you have the right to advise your broker, bank or other agent about dividend shares and how they are reflected in your account.Your broker can also help you get paid in lieu of cash, if applicable.
P:What if I do not receive the Information Statement or Dividend Confirmation?
A: A copy of the Information Statement is attached to this FAQ asAppendix A.
Registered Shareholder: Shares registered in your name
To obtain a copy of your dividend confirmation or to verify the status of your cash payment (if applicable), please contact Scilex's transfer agent, CST, by telephone or email at:
Continental Stock Transfer & Trust Company
Phone number: 800-509-5586
email address:
Beneficial Owner: Shares registered in the name of a broker, bank or other agent
If you hold your shares in "name of the street" through a brokerage, bank, dealer or other similar organization, that organization has received a dividend confirmation with respect to all dividend shares held by its customers and its share. be reflected on account statements you receive from your broker, bank, dealer or other similar organization.
NoAppendix Bof these FAQs.
IF YOU HAVE ANY QUESTIONS REGARDING YOUR ACCOUNT STATEMENT OR ANY OTHER COMMUNICATION FROM YOUR BROKER OR OTHER AGENT REGARDING DIVIDEND SHARES, PLEASE CONTACT US IMMEDIATELY.
P:Why does my brokerage statement indicate that dividend shares are worthless?
A: If your brokerage statement indicates that the dividend stock is worthless, contact your brokerage, bank, dealer or other similar organization immediately to ensure your brokerage statement is accurate and reflects the value of the dividend stock .
NoAppendix Bof these FAQs.
P:What is the value of dividend shares?
A: Scilex common stock is listed on Nasdaq Stock Market LLC under the symbol "SCLX". You can get the trading and closing prices of Scilex common stock on the Nasdaq website at Nasdaq.com.
P:What is the CUSIP number of Scilex common shares?
R: CUSIP number of Scilex 80880W106.
P:Is there a separate CUSIP number for dividend shares?
AN:Do not.The CUSIP number for dividend shares is the same as for all other Scilex common shares.
P:My brokerage statement references an ISIN. What is an ISIN?
A: ISIN stands for International Securities Identification Numbering System and is the global ISO standard for the unique identification of financial and reference instruments, including equities, debt, derivatives and indices.
Note that the ISIN is not the CUSIP number. You should contact your broker immediately for more ISIN information and to have the broker include the Scilex CUSIP number on your brokerage statement.
P:May I transfer, sell, pledge, lend or otherwise dispose of and transfer the dividend shares?
AN:Not. The dividend shares you will receive on the payment date are subject to transfer restrictions until May 11, 2023 and your dividend shares will reflect the following restrictive caption, which restriction is also included in your Dividend Confirmation:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, MORTGAGED, LOANED, FOUND OR OTHERWISE MADE AVAILABLE WITHOUT THE CONSENT OF SCILEX HOLDING COMPANY (THE “COMPANY”) BEFORE MAY 11, 2023.A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A) SALE OR ASSIGNMENT OF, OFFER TO SALE, CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY PURCHASE OPTION OR PROVISION OR AGREEMENT TO PROVIDE, DIRECTLY OR INDIRECTLY, OR BY ESTABLISHING OR INCREASING AN EQUIVALENT SELL OR NET POSITION WITH RESPECT TO OR DECREASING AN EQUIVALENT CALL POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”), WITH RESPECT TO ANY SECURITIES OF THE COMPANY, (B) ENTER INTO ANY EXCHANGE OR OTHER AGREEMENT WHICH TRANSFERS TO ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITIES OF THE COMPANY, WHETHER ANY TRANSACTION IS SETTLED BY THE DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C) THE COMMITMENT, WHETHER DIRECTLY OR INDIRECTLY, IN ANY (I) “CASH SALES” (AS PER ME SUCH TERM IS DEFINED IN RULE 200 OF THE SHO RULE OF EXCHANGE ACT) OR F OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II) HEDGING TRANSACTION, WHICH ESTABLISHES A NET ADVANTAGE POSITION IN RELATION TO ANY SECURITIES OF THE COMPANY (INCLUDING THE SHARES ORDINARY ACCOUNTS OF THE COMPANY, WITH RESPECT TO EACH OF THE SECTIONS (I) AND (II)) OF THE PRESENT, WHETHER FOR THE MAIN ACCOUNT OF THE HOLDER OR FOR THE MAIN ACCOUNT OF ANY OTHER PERSON.
P:When can I transfer, sell, pledge or otherwise dispose of and transfer the dividend shares?
A: Previous transfer restrictions on dividend shares will be lifted on May 12, 2023, with no action required from you.
Q: If I loaned my shares of Sorrento common stock to short sellers or any other party on the Record Date, am I still entitled to receive dividend shares on the Payment Date?A: Only Registration Holders on the Registration Date are entitled to receive Dividend Shares. If you were the Record Holder on the Record Date and you are entitled to receive the dividend shares but have not received the dividend shares, you may be entitled to receive the dividend shares from the short seller or other party that lent your shares Ordinary Sorrento. shares, whether through lending programs implemented by your brokerage, bank, dealer or other similar organization or otherwise. If you were a Record Holder on the Record Date and did not receive your Stock Dividends, consult your financial adviser, stockbroker or other agent immediately to determine how to receive your Stock Dividends.
P:What if my Sorrento common stock were sold "short" on the Record Date?
A: According to Sorrento's estimates, approximately 60 million or more shares of Sorrento common stock were sold "short" on the Record Date. If your shares of Sorrento common stock were held through a broker, bank, dealer or other similar organization and sold "short" on the Record Date, you should consult your financial adviser, broker or other agent immediately to determine whether you also may be considered "short" ordinary shares of Scilex as a result of the Dividend, as well as any obligation required of you to protect your "short" position(s).
Note that "naked short" sales or "naked short" positions insomeSorrento common stock may violate SEC SHO Rules.
P:What happens if my Scilex common shares issued as dividend shares are sold "short" because my Sorrento common shares were sold "short" on the payment date?
A: According to Sorrento's estimates, approximately 8.4 million or more shares of Scilex common stock were considered "short" on the payment date as a result of the aforementioned "short" positions of the underlying shares of Sorrento common stock.
If your Scilex common shares issued as dividend shares are held through a broker, bank, dealer or other similar organization and are deemed to have sold "short" on the payment date as a result of a "price" in the underlying common shares shares listed above, you should consult your financial adviser, stockbroker or other agent immediately to determine the liabilities required to cover your “short” positions in Scilex common stock.
Note that "naked short" sales or "naked short" positions insomeScilex common stock may violate SEC SHO Rules.
P:If I am considered to be a "short" stock split of Scilex, what is the borrowing cost for my "short" position in Scilex common stock?
A: Based on recent reports from several brokerages that lend Scilex common stock for "short" sales, it is estimated that the current lending interest rate is in excess of 400% per annum. If your Scilex common stock is held by a broker, bank, dealer or other similar organization and you are "short", consult your financial adviser, broker or other agent immediately to determine your interest rate. position. ” position(s) of Scilex common shares.
Note that "naked short" sales or "naked short" positions insomeScilex common stock may violate SEC SHO Rules.
P:What is the estimated “short” position of Scilex common stock on the payment date?
A: According to Sorrento's estimates, approximately 8.4 million or more shares of Scilex common stock sold "short" on the payment date.
If your Scilex common shares are held by a broker, bank, dealer or other similar organization and your Scilex common shares are sold "short" on the Payment Date, you should consult your financial adviser, broker or other agent immediately. to determine the liabilities required to cover your "short" position(s) of Scilex common stock.
Note that "naked short" sales or "naked short" positions insomeScilex common stock may violate SEC SHO Rules.
P:What is the public float (ie unrestricted and freely traded shares) of Scilex common stock on the payment date?
A: Approximately 2.5 million shares of Scilex common stock were freely transferable with no payment date restrictions. This public float may be increased if some or all of the unrestricted and freely tradable "public" warrants are exercised to purchase shares of Scilex common stock. The strike price of Scilex's “public” warrants is $11.50 per share (subject to adjustments for recapitalizations, stock splits and similar transactions and as provided in the warrants).
P:How many Scilex warranties are currently outstanding?
A: There are approximately 11 million unrestricted and freely negotiable warrants to purchase outstanding shares of Scilex common stock and such warrants have an exercise price of $11.50 per share (subject to adjustments for recapitalizations, stock splits and transactions similar and depending on the provisions of the warrant). Sorrento holds approximately 4.5 million Scilex warrants (of which approximately 3.1 million are Private Warrants) and Vickers Venture Fund VI Pte Ltd and its affiliates hold one million Scilex Private Warrants.
P:Will Scilex management take action with respect to substantial "covered" positions in Scilex common stock that represent approximately three times the public float of Scilex common stock?
A: Yes. The management teams of Scilex and Sorrento are in consultation with their external legal counsel to explore all legal means to resolve the imbalance of substantial "short" positions of Scilex common stock estimated at approximately 8.4 million or more shares of common stock from Scilex. compared to the limited public float of approximately 2.5 million shares of Scilex common stock.
Scilex and Sorrento will send written notice to the Financial Industry Regulatory Authority (FINRA), which oversees US brokerages, to inform FINRA of "unhedged short" positions, "substantial actions in Scilex common stock. Sorrento and Sorrento Scilex will offer to work closely with FINRA and other regulatory agencies to enforce applicable laws, rules and regulations governing market participants, which strictly prohibit intentional or abusive "short selling" of securities listed.
Appendix A
information statement
January 10, 2023
Dear Shareholder of Sorrento Therapeutics, Inc.:
Como Sorrento Therapeutics, Inc. (“Sorrento”), previously announced, on December 29, 2022 our board of directors declared a stock dividend (the “dividing”) composed of a total of 76,000,000 shares (the “dividend stock”) of common stock, par value $0.0001 per share, of Scilex Holding Company (“Scilex common shares) held by Sorrento for registered holders of (i) shares of Sorrento common stock, par value $0.0001 per share (such shares, the "Sorrento Common Stock” and such record holders, the “Register of Common Owners”) as of the close of business on January 9, 2023 (the “recording date”), and (ii) certain warrants to purchase Sorrento common stock that, among other things, were not exercised prior to the ex-dividend date pursuant to Nasdaq Stock Market LLC rules (and which are or may be entitled to participate in the Dividend pursuant to the terms of their respective warrants) (the “Search warrant holders” and together with the Common Record Holders, the “record holders”), whose Dividend will be paid on January 19, 2023 (the “Payday”) and will be distributed pro rata among the Record Holders in accordance with each Record Holder's percentage ownership of Sorrento common stock (assuming full exercise of all outstanding warrants to purchase Sorrento common stock) from from the Registration Date as defined in the transfer agent records of Sorrento (with respect to Common Registrar Holders) and Sorrento (with respect to Registrar Warrant Holders) from that date.
Scilex Holding Company (“escilex”) is the majority-owned public information subsidiary of Sorrento and Scilex common stock is currently listed and traded on the Nasdaq Capital Market under the symbol “SCLX”. As a public reporting firm, Scilex files periodic reports and other information with the SEC, which reports and other information can be found on the Securities and Exchange Commission website at.
Each Ordinary Registration Holder will receive (and each applicable Registration Warrant Holder will be entitled to receive upon the exercise of such holder's applicable warrants) 0.1410127 of a common share of Scilex for each (1) common share of Sorrento held (or applicable underlying security) by such Registration Holder at the time of close of business on the Registration Date. The dividend shares will be subject to certain transfer restrictions until May 11, 2023, as more fully described in the accompanying information statement and notice. Payment of the dividend is conditional on the non-revocation of the dividend before the payment date by the Sorrento Board of Directors.
The stock dividend will be paid in an uncertified (ie book-entry) manner, which means that no physical stock certificates will be issued to you. No fraction of Scilex common shares will be issued in the Dividend. To the extent that a Sorrento Record Holder is entitled to receive fractional shares of Scilex common stock in the Dividend, such holders shall receive cash (without interest or deductions) in lieu of such fractional shares in an amount equal to the product obtained by multiplying (a) the closing price of Shares of Scilex Common Stock on the Nasdaq Stock Market on the Record Date, by (b) the fraction of one share of Shares of Scilex Common that such shareholder would be entitled to receive as a Dividend in respect of the common shares of Sorrento held by such Record Holder (after summing up all fractional shares that could be issued to such shareholder in connection with the Dividend).
You should consult your own tax advisor regarding the specific tax consequences of the Dividend, including potential tax consequences under state, local and non-US tax laws.
The Dividend does not require the approval of Sorrento shareholders and you are not required to take any action to receive your Dividend Share. Upon payment of the Dividend, you will own common shares in both Sorrento (if you hold such shares after the Record Date) and Scilex. Sorrento common stock will continue to trade on the Nasdaq Capital Market under the symbol "SRNE" and Scilex common stock will continue to trade on the Nasdaq Capital Market under the symbol "SCLX".
Scilex is an innovative, revenue-generating company focused on the acquisition, development and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Scilex believes that its innovative portfolio of non-opioid products has the potential to provide effective pain management therapies that can have a transformative impact on patients' lives. Scilex focuses on indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes.
We want to thank you for your support of Sorrento (including our subsidiary, Scilex) and it is a great privilege to welcome you as a future Scilex shareholder and we look forward to your continued support in the future.
The accompanying information statement and notice, which we mail to all Sorrento shareholders at close of business on the Record Date, describes the Dividend and directs you to important business and financial information about SCLX, including Scilex's strategy and plans. in the short and long term. deadline. long-term growth to create value for its shareholders. We ask that you read this notice and information statement carefully.
Carefully,
Henry Ji, Ph.D.
Chairman of the Board of Directors, CEO and President of Sorrento Therapeutics, Inc. and Executive Chairman of Scilex Holding Company
INFORMATION STATEMENT
Y
NOTICE UNDER SECTION 151(F) AND SECTION 202
DELAWARE GENERAL PARTNERSHIPS ACT
COMPANY HOLDING SCILEX
Common stock, par value $0.0001 per share
Unless the context otherwise requires, references in this information statement to "we", "us", "our", "Scilex" and "the Company" generally refer to Scilex Holding Company together with its subsidiaries.
This information statement and notice pursuant to Section 151(f) and Section 202 of the Delaware General Corporation Law (“DGCL”), including the accompanying Summary of Dividends, is provided to you as a holder of common stock of Sorrento Therapeutics, Inc. (“Sorrento”). As Sorrento previously announced, on December 29, 2022, the Sorrento Board of Directors (the “Sorrento sign”) declared a stock dividend (the “dividing”) composed of a total of 76,000,000 shares (the “dividend stock”) of common stock, par value $0.0001 per share, of Scilex Holding Company (“Scilex common shares) held by Sorrento for registered holders of (i) shares of Sorrento common stock, par value $0.0001 per share (such shares, the "Sorrento Common Stock” and such record holders, the “Register of Common Owners”) as of the close of business on January 9, 2023 (the “recording date”), and (ii) certain warrants to purchase Sorrento common stock that, among other things, were not exercised prior to the ex-dividend date pursuant to Nasdaq Stock Market LLC rules (and which are or may be entitled to participate in the Dividend pursuant to the terms of their respective warrants) (the “Search warrant holders” and together with the Common Record Holders, the “record holders”), whose Dividend (unless otherwise determined by the Board) will be paid on January 19, 2023 (the “Payday”) and will be distributed pro rata among the Record Holders in accordance with each Record Holder's percentage ownership of Sorrento common stock (assuming full exercise of all outstanding warrants to purchase Sorrento common stock) from from the Registration Date as defined in the transfer agent records of Sorrento (with respect to Common Registrar Holders) and Sorrento (with respect to Registrar Warrant Holders) from that date.
We are a majority-owned public information subsidiary of Sorrento (currently owning 96.7% of our currently outstanding voting shares). Scilex common stock is currently listed and traded on the Nasdaq Capital Market under the symbol "SCLX". As a public reporting company, Scilex submits periodic reports and other information to the Securities and Exchange Commission ("SECOND”), whose reports and other information can be found on the CVM website at.
Scilex is an innovative, revenue-generating company focused on the acquisition, development and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Scilex believes that its innovative portfolio of non-opioid products has the potential to provide effective pain management therapies that can have a transformative impact on patients' lives. Scilex focuses on indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex launched its first commercial product in October 2018 and is developing its late-stage pipeline, which includes a Phase 3 lead candidate, a Phase 2 candidate and a Phase 1 candidate expected to enter studies. of Phase 2 in the first half of 2023. Scilex commercial product, ZTlido (topical lidocaine system) 1.8% (“ZTlido”) is a topical prescription lidocaine product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of nerve pain following shingles. ZTlido features a new delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches, providing significantly improved adhesion and continued pain relief during the 12-hour delivery period.
On the Dividend Payment Date, each Registered Ordinary Holder will receive (and each applicable Registered Warrant Holder will be entitled to receive upon the exercise of such relevant Warrants) 0.1410127 of a common share of Scilex for each (1) share of Sorrento Common Shares held (or underlying the corresponding warrants) by such Record Holder at close of business on the Record Date. In lieu of receiving fractional shares of Dividend Shares that would otherwise be allocated to the Registered Ordinary Holder, each Registered Ordinary Holder will receive cash representing the fair market value of such fractional shares. Dividend Shares will be subject to certain transfer restrictions until May 11, 2023, as described below. Payment of the dividend is conditional on Sorrento Council not revoking the dividend prior to the payment date.
Immediately after Sorrento completes the Dividend, Sorrento will own approximately 52.1% of our currently outstanding voting shares.
You should consult your tax advisor regarding the specific federal, state, local and non-US tax consequences to you of receiving the Dividend..
If you are a corporate US Holder (as defined below), you may be eligible for a dividend received deduction (subject to certain requirements and limitations) in connection with your receipt of the Dividend, but the Dividend may be subject to certain "extras" " dividends” of the United States Internal Revenue Code of 1986, as amended (the “Code”). Such disposals could result in a reduction in the adjusted basis of your Sorrento common stock and potentially gain recognition.
If you are a non-corporate US Holder (as defined below), the Dividend (including cash payment in lieu of fractional shares) delivered to you may be subject to a security withholding at a rate of 24% of the market value of such Dividend , unless you provide a correct taxpayer identification number by submitting a properly completed IRS Form W-9 (or successor form).
If you are not a US Holder (as defined below), the Dividend (including cash payment in lieu of fractional shares) delivered to you may be subject to withholding tax at a rate of 30% of the fair market value of the mentioned Dividend. unless you establish an entitlement to a reduced rate of withholding by providing a duly signed IRS Form W-8 BEN, W-8BEN-E, or other applicable IRS Form W-8 (or successor form).
As used above, a "USA headline” is a beneficial owner of the shares of Sorrento common stock who, for US federal income tax purposes, is (a) a person who is a citizen or resident of the United States; (b) a corporation created or organized under the laws of the United States, any of its states or the District of Columbia; (c) an estate the income of which is subject to US federal income tax, regardless of source; or (d) a trust, if a court in the United States can exercise primary supervision over the administration of the trust and one or more United States persons have authority to control all material decisions of the trust, or, if the trust exists on 20 August 1996 and chose to continue to be treated as a United States citizen.
The Dividend (including the cash payment in lieu of fractional shares of Dividend Shares) may be included in ordinary taxable income for you in the year including the Payment Date to the extent of a share of Sorrento's current and retained earnings and earnings. To the extent that the fair market value of the Dividend exceeds Sorrento's current and retained earnings and earnings, the Dividend will first be treated as a return on a non-taxable basis, and any amount exceeding that adjusted basis will constitute a capital gain. .
You do not need any votes or any other shares to receive dividend shares. You will not be obligated to pay Sorrento or Scilex anything for the new shares or to surrender any of your Sorrento common shares. We are not asking for a power of attorney and you should not send us a power of attorney or your stock certificates.
In reviewing this information statement, you should carefully review the reports and other information we have filed with the SEC and specifically refer you to our (i) registration statement on Form S-4 (File #333-264941), including the appendices and exhibits thereof, pursuant to the Securities Act initially filed with the Securities and Exchange Commission ("SEC") on May 13, 2022 (as later amended), which was declared to be effective by the SEC on May 28, 2022 in October, 2022 (the "registration statement”), (ii) final prospectus with respect to the Registration Statement, filed with the SEC on October 28, 2022 (the “user information”), and (iii) Current Report on Form 8-K, filed with the SEC on November 17, 2022 (the “Opponent 8-K” and together with the Registration Statement and the Prospectus, the “promotional materials”).
You should also carefully review the risks and uncertainties described under the heading "Risk Factors" in the Registration Statement and Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this informational statement is true or complete. Any statement to the contrary is a criminal offence.
This information statement does not constitute an offer to sell or the solicitation of an offer to buy any securities.
The date of this information statement and notice pursuant to Section 151(f) and Section 202 of the DGCL is January 10, 2022.
| DIVIDEND SUMMARY | |
| Distribution company: | Sorrento Therapeutics, Inc. |
| Distributed Company: | Scilex Holding Company, a majority-owned public information subsidiary of Sorrento |
| Dividend Inventory: | Sorrento will distribute a total of 76,000,000 common shares of Scilex in the Dividend. |
| Dividend Rate: | Each Ordinary Registration Holder will receive (and each applicable Registration Warrant Holder will be entitled to receive upon the exercise of such holder's applicable warrants) 0.1410127 of a common share of Scilex for each (1) common share of Sorrento held (or applicable underlying security) by such Registration Holder at the time of close of business on the Registration Date. |
| Treatment of fractional shares: | No fractional shares will be issued in connection with the Dividend and Record Holders who would otherwise be entitled to receive fractional shares of Scilex common stock will receive cash (without interest or deductions) in lieu of such fractional shares in an equal amount to the product obtained by multiplying (a) the closing price of Scilex common stock on the Nasdaq capital market on the registration date by (b) the fraction of one share of Scilex common stock that the registrant would otherwise would be entitled to receive as a Dividend in respect of shares of Sorrento common stock held by such Registration Holder (after adding all fractional shares that could be issued to such Registration Holder in connection with the Dividend). |
| Recording date: | January 9, 2023 |
| Payday: | January 19, 2023 |
| Dividend: | On the Payment Date, Sorrento, with the assistance of Continental Stock Transfer & Trust Company, Scilex's transfer agent (“Continental”), will distribute shares of Scilex common stock to you electronically via a registered position with Continental until the expiration of the lock-up period described below. You will not be obligated to make any payments to Sorrento or Scilex or to deliver or exchange your Sorrento common shares in order to receive your Scilex common shares on the payment date. |
| Scilex Common Stock Market: | Our common shares trade on the Nasdaq Capital Market under the symbol “SCLX”. |
| Transfer agent for Scilex: | Continental Stock Transfer & Trust Company |
| Notice of Transfer Restrictions: | Notice is given pursuant to Sections 151(f) and 202 of the Delaware General Corporation Law (“DGCL”), that the Scilex common shares you will receive as a Dividend will be issued to you in uncertified form (i.e. accounting entries). The Dividend Shares you will receive on the Payment Date will be subject to transfer restrictions until May 11, 2023 and your Dividend Share shares will reflect the following restrictive legend: THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, MORTGAGED, LOANED, FOUND OR OTHERWISE MADE AVAILABLE WITHOUT THE CONSENT OF SCILEX HOLDING COMPANY (THE “COMPANY”) BEFORE MAY 11, 2023.A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A) SALE OR ASSIGNMENT OF, OFFER TO SALE, CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY PURCHASE OPTION OR PROVISION OR AGREEMENT TO PROVIDE, DIRECTLY OR INDIRECTLY, OR BY ESTABLISHING OR INCREASING AN EQUIVALENT SELL OR NET POSITION WITH RESPECT TO OR DECREASING AN EQUIVALENT CALL POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”), WITH RESPECT TO ANY SECURITIES OF THE COMPANY, (B) ENTER INTO ANY EXCHANGE OR OTHER AGREEMENT WHICH TRANSFERS TO ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITIES OF THE COMPANY, WHETHER ANY TRANSACTION IS SETTLED BY THE DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C) THE COMMITMENT, WHETHER DIRECTLY OR INDIRECTLY, IN ANY (I) “CASH SALES” (AS PER ME SUCH TERM IS DEFINED IN RULE 200 OF THE SHO RULE OF EXCHANGE ACT) OR F OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II) HEDGING TRANSACTION, WHICH ESTABLISHES A NET ADVANTAGE POSITION IN RELATION TO ANY SECURITIES OF THE COMPANY (INCLUDING THE SHARES ORDINARY ACCOUNTS OF THE COMPANY, WITH RESPECT TO EACH OF THE SECTIONS (I) AND (II)) OF THE PRESENT, WHETHER FOR THE MAIN ACCOUNT OF THE HOLDER OR FOR THE MAIN ACCOUNT OF ANY OTHER PERSON. In addition, please note that the Company will provide, free of charge, to each shareholder of the Company who so requests, the powers, appointments, preferences and rights relating to, participation, options or other special rights of each class or series of shares. themselves, the Company and the qualifications, limitations or restrictions of such preferences and/or rights, which are set forth by the Company's amended Incorporation Act, as amended from time to time. Any such request should be addressed to the Company Secretary. |
| US Federal Income Tax Consequences: | The Dividend (including the cash payment in lieu of fractional shares of Dividend Shares) may be included in ordinary taxable income for you in the year including the Payment Date to the extent of a share of Sorrento's current and retained earnings and earnings. To the extent that the fair market value of the Dividend exceeds Sorrento's current and retained earnings and earnings, the Dividend will first be treated as a return on a non-taxable basis, and any amount exceeding that adjusted basis will constitute a capital gain. . If you are a corporate US Holder, you may be entitled to a dividend received deduction (subject to certain requirements and limitations) in connection with your receipt of the Dividend, but the Dividend may be subject to certain "extra dividend" provisions of the Code. Such disposals could result in a reduction in the adjusted basis of your Sorrento common stock and potentially gain recognition. If you are not a US Holder, the Dividend to be paid to you may be subject to withholding tax at a rate of 30% of the fair market value of such Dividend, unless you establish a right to a withholding rate reduced by providing an executed IRS Form W-8 BEN, W-8BEN-E, or other applicable IRS Form W-8 (or successor form). This discussion does not cover all aspects of US federal income tax. In addition, the above discussion is based on the provisions of the Code and Treasury regulations, rulings, and court decisions under the Code as of the date of the Code. present, and such authorities may be revoked, revoked or modified, possibly retroactively, and are subject to different interpretations which may have US federal tax consequences other than those discussed above. You should consult your tax advisor regarding the specific federal, state, local and non-US tax consequences to you of receiving the Dividend. |
| Corporate information: | We were incorporated under the name "Vickers Vantage Corp. I" on February 21, 2020 as a Cayman Islands exempt company for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or business combination similar with one or more companies. or entities. On November 9, 2022, we changed our jurisdiction of incorporation by deregistering as an exempt Cayman Islands corporation and proceeding and naturalizing ourselves as a corporation incorporated under the laws of the State of Delaware. On November 9, 2022, we changed our name to "Scilex Holding Company". Our main executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) 516-4310. Our website address is. Any information contained on or accessible through our website is not incorporated by reference or in any way a part of this information statement and notice, and should not be relied upon in connection with making a decision about an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You can obtain any of the documents filed by us with the SEC free of charge on the SEC's website at. |
| Risk factors: | Owning Scilex common stock involves a high degree of risk. You should carefully read the risk factors as well as other information set forth in the Disclosure Materials (as defined below), including the matters addressed in the section entitled "Cautionary Note Regarding Forward-Looking Statements" (set out in the Disclosure Materials). |
| WHERE CAN YOU FIND MORE INFORMATION? | |
| In connection with the completion of our previously announced business combination with Vickers Vantage Corp. I on November 10, 2022 (the “business combination”), we have filed (i) a registration statement on Form S-4 (File No. 333-264941), including exhibits, pursuant to the Securities Act, initially filed with the SEC on May 13, 2022 (as amended subsequent) and which was declared effective by the SEC on October 28, 2022 (the “registration statement”), (ii) a final prospectus with respect to the Registration Statement, filed with the SEC on October 28, 2022 (the “user information”), and (iii) a Current Report on Form 8-K, filed with the SEC on November 17, 2022 (the “Opponent 8-K” and together with the Registration Statement and the Prospectus, the “promotional materials”). The Disclosure Materials contain detailed information about, among other things, our business, management, directors and officers compensation, financial condition (including pro forma information relating to the Business Combination), historical financial statements and our management's discussion and analysis of our finances condition and results). operations), a description of our values and certain related party relationships and transactions. If you wish to request a copy of any of the Disclosure Materials, you may do so by contacting Angela Lamb at our transfer agent (Pacific Stock Transfer Company) via email at or by phone at702-361-3033and such materials will be provided to you free of charge. In addition, as a reporting firm, we also file periodic reports and other information with the SEC. The SEC maintains a website that contains such reports and other information about issuers that file electronically with the SEC, including Scilex Holding Company. The SEC's website can be found at. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC on the SEC's website at. We also maintain a website at. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably possible after they are filed electronically or filed with the SEC. The information contained on or accessible through our website is not part of or incorporated into this information and notice statement, and the inclusion of our website address in this information and notice statement is an inactive textual reference only. | |
Appendix B
list of runners
| broker name | Broker direction | broker name | Broker direction | |
| ABN AMRO CLEARING CHICAGO LLC | 175 WEST JACKSON BLVD. CHICAGO ILLINOIS 60604 EE. UU. | Albert Fried & Company LLC | 45 BROADWAY, PISO 24 PISO 24 NEW YORK NEW YORK 10006 EE. UU. | |
| INCORPORATED BANK | 275 7th AVENUE NEW YORK NEW YORK 10003 EE. UU. | AMERICAN COMPANY INVESTMENT SERVICES INC. | 682 AMERIPRISE FINANCIAL CENTER MINNEAPOLIS Minnesota, Minnesota 55474 EE. UU. | |
| APEX COMPENSATION CORPORATION | 2 ENTRY CENTER 283-299 MARKET ST PISO 16 NEWARK NJ NEW JERSEY 07102-5005 EE. UU. | BANK OF AMERICA, NA/GWIM TRUST OPERATIONS | MAIN STREET 901 PISO 12 DALLAS Texas Texas 23113 United States | |
| BANK OF NEW YORK MELLON | 111 SANDERS CREEK PARKWAY 2.° PISO 2° PISO ORIENTAL SYRACUSE NEW YORK 13057 EE. UU. | BARCLAYS CAPITAL INC. | DTC CUSTODY PARTNER - NY WINDOW -570 WASHINGTON BLVD (ATTENTION: ROSA HICKS-MILLER OR ROBERT MENDEZ JERSEY CITY NJ NEW JERSEY 07310 United States | |
| BARCLAYS CAPITAL INC. | DTC CUSTODY PARTNER - NY WINDOW -570 WASHINGTON BLVD (ATTENTION: ROSA HICKS-MILLER OR ROBERT MENDEZ JERSEY CITY NJ NEW JERSEY 07310 United States | BMO CAPITAL MARKETS CORP. | 3 CALL 2 PISO 12 JERSEY CITY NJ NEW JERSEY 07302 EE. UU. | |
| BMO HARRIS BANK NA/TRUST | 11270 W PARQUE PL MILWAUKEE WI WISCONSIN 53224EE. UU. | BMO Nesbitt Burns Inc., Toronto | 250 CALLE YONGE, PISO 7 SEVENTH FLOOR TORONTO IT'S ONTARIO M5B 2M8 CA CANADA | |
| BNP PARIBAS, NEW YORK AGENCY/CUSTODIAN BNP PARIBAS PRIME CORRETORA | 100 WEST 33RD STREET 3rd WALK NEW YORK NEW YORK 10001 | BNP PARIBAS, NEW YORK AGENCY/CUSTODIAN BNP PARIBAS PRIME CORRETORA | 100 WEST 33RD STREET 3rd WALK NEW YORK NEW YORK 10001 | |
| BNY MELLÓN | PO Box 392002 500 ROSS CALLE PITTSBURGH pennsylvania pennsylvania 15262 EE. UU. | BNY MELLON/WEALTH MANAGEMENT | 1 UNIT FREEDOM VALE ROBLES pennsylvania pennsylvania 19456 EE. UU. | |
| BNYMELLON | 111 SANDERS CREEK PARKWAY 2.° PISO 2° PISO ORIENTAL SYRACUSE NEW YORK 13057 EE. UU. | BNYMELLON/RE BARCLAYS CAPITAL SECURITIES LTD. | A WALL STREET NEW YORK NEW YORK 10286 | |
| BNYMELLON/RE CACEIS BANK LUXEMBOURG | 500 Grant St. Centro BNY Mellon PITTSBURGH pennsylvania pennsylvania 15258 | BNYMELLON/RE CACEIS BANK, THE NETHERLANDS | 111 SANDERS CREEK PARKWAY ORIENTAL SYRACUSE NEW YORK 13057 | |
| BNYMELLON/RE CHARLES STANLEY AND COMPANY, LIMITED | 111 SANDERS CREEK PARKWAY 2.° PISO 2° PISO ORIENTAL SYRACUSE NEW YORK 13057 EE. UU. | BNYMELLON/RE ETF - ASSETS DTC/NSCC | 111 SANDERS CREEK PARKWAY ORIENTAL SYRACUSE NEW YORK 13057 | |
| BNYMELLON/RE WINTERFLOOD SECURITIES LTD | 500 Grant St. Centro BNY Mellon PITTSBURGH pennsylvania pennsylvania 15258 | BOFA | 4804 Deer Lake Drive Este FL9-803-04-04- 4to piso JACKSONVILLE FL FLORIDA 32246 EE. UU. | |
| BOFA | 4804 Deer Lake Drive Este FL9-803-04-04- 4to piso JACKSONVILLE FL FLORIDA 32246 EE. UU. | BOFA VALUES INC. | 4804 Deer Lake Drive Este FL9-803-04-04- 4to piso JACKSONVILLE FL FLORIDA 32246 EE. UU. | |
| BROWN BROTHERS HARRIMAN & CO. | 140 BROADWAY ATTENTION: CORPORATE SAFE NEW YORK NEW YORK 10005 EE. UU. | BROWN BROTHERS HARRIMAN & CO./ETF | 140 BROADWAY NEW YORK NEW YORK 10005 | |
| CALDWELL VALUES LTD./CDS** | AVENIDA UNIVERSITÁRIA 55 SUITE 340 TORONTO IT'S ONTARIO M5J 2H7 CANADA | CANACCORD GENUITY CORP. | 609 GRANVILLE ST VANCOUVER BC BRITISH COLUMBIA V7Y 1H2 CA CANADA | |
| CANTOR, FITZGERALD & CO. | 135 E 57TH ST 5TH FL NEW YORK NEW YORK 10041 EE. UU. | CDS INC. CLEARING AND DEPOSIT SERVICES | 100 WEST ADELAIDE STREET TORONTO IT'S ONTARIO M5H 1S3 CA CANADA | |
| CETERA INVESTMENT SERVICES LLC | 400 FIRST SOUTH STREET, SUITE 300 SUITE 300 ST. CLOUD Minnesota, Minnesota 56302-0283 EE. UU. | CHARLES SCHWAB & CO., INC. | MAIN STREET 211 SAN FRANCISCO CA CALIFORNIA 94105 EE. UU. | |
| CI INVESTMENT SERVICES INC. | 199 BAY STREET SUITE 2600 TORONTO IT'S ONTARIO M5L 1E2 CA CANADA | CIBC WORLD MARKETS INC./CDS** | 161 BAY STREET 10 FL TORONTO IT'S ONTARIO M5J 2S8 CA CANADA | |
| CITIBANK, NA/ETF | 3800 CITIGROUP CENTER B2/2 TAMPA FL FLORIDA 33610 | CITIBANK, NATIONAL ASSOCIATION | 3800 CENTRO CITIBANK TAMPA BUILDING B FIRST FLOOR ZONE 8 TAMPA FL FLORIDA 33610-9122EE. uu. | |
| CITIGROUP GLOBAL MARKETS, INC. | 580 PARKWAY CROSSING POINTS GETZVILLE NEW YORK 14068 EE. UU. | CLEAR STREET LLC | 4 World Trade Center, piso 45 Rua Greenwich 150 NEW YORK NEW YORK 10007 | |
| CALLE CLEAR IO | 55 BROADWAY (SUITE 2102) CORPORATE SHARES NEW YORK NEW YORK 10006 EE. UU. | COMMERCIAL BANK | 922 CALLE QUITE TBTS-2 MAIL STOP KANSAS CITY Measurements 64106 EE. UU. | |
| COR CLEARING LLC | 9300 UNDERWOOD AVE SUITE 400 OMAHA NE NEBRASKA 68114 E.E. UU. | Credential Securities Inc. | 800-1111 CALLE GEORGIA OCCIDENTAL VANCOUVER BC BRITISH COLUMBIA V6E 4T6 CA CANADA | |
| CREST INTERNATIONAL NOMINEES LIMITED | 33 CALLE CANON LONDON EC4M 5SB GB UK | CURVATURE VALUES, LLC | 39 MAIN STREET CHATAM NJ NEW JERSEY 07928 EE. UU. | |
| FROM DAVIDSON AND COMPANY. | 8 3rd NORTH STREET BIG FALLS MOUNTAIN MOUNTAIN 59401 EE. UU. | DEPOSITO CENTRAL DE VALORES S.A., DEPOSITO DE VALORES MOBILIÁRIOS | 4001 APOCUIND AVENUE FLOOR 12, ZIP 7550162, SANTIAGO CL CHILE | |
| DESJARDINS SECURITIES INC. | 1253 McGill College PISO 10 MONTREAL QUEBEC H3B 2Y5 CA CANADA | DEUTSCHE BANK AG NY/USA CUSTOMER | Avenue of the Americas 1251 NEW YORK NEW YORK 10020 | |
| DEUTSCHE BANK SECURITIES INC. | 60 MALLADA STREET PISO 9 NEW YORK NEW YORK 10005 EE. UU. | DRIVEWEALTH, LLC | 15 EXCHANGE PLACE PISO 10 JERSEY CITY NEW JERSEY 07302 | |
| E*TRADE CLEARING LLC | PORTO FINANCIAL CENTER 501 PLAZA 11 JERSEY CITY NJ NEW JERSEY 07311 United States | EDWARD D. JONES & CO., L.P. | 12555 MANCHESTER ROAD ST. T. LOUIS Measurements 63131-3729 EE. UU. | |
| EDWARD D. JONES & CO., L.P. | 201 PROGRESS PARKWAY HEIGHTS OF MARYLAND Measurements 63043 EE. UU. | LOYALTY COMPENSATION CANADA ULC/CDS** | R. BAHIA, 483. TORRE ON TORONTO IT'S ONTARIO M5G2N7 CA CANADA | |
| FIFTH THIRD BANK | 5001 KINGSLEY DRIVE SEND MAIL 1MOB28 CINCINNATI OH OHIO 45227 EE. UU. | FOLIO INVESTMENTS, INC. | 8180 GREENSBORO DRIVE PISO 8 MILLIONAIRE VA VIRGINIA 22102 EE. UU. | |
| FUTU CLEARING INC. | 12750 Merit unit SUITE 475 DALLAS Texas Texas 75251 | GMP L.P. VALUES | KING STREET WEST, 145, SUITE 300 PISO 11 TORONTO IT'S ONTARIO MJ5 1J8 CA CANADA | |
| GOLDMAN, SACHS & CO. LLC | MAIN STREET 222 IN Attention: Mandatory Corporate Actions SALT LAKE CITY UT UTAH 84101 EE. UU. | HAYWOOD SECURITIES INC./CDS** | 200 BURRARD ST SUITE CENTRO BEIRA-MAR 700 VANCOUVER BC BRITISH COLUMBIA V6C 3L6 CANADIA | |
| HILLTOP SECURITIES INC. | 1201 ELM ST. PISO 35 DALLAS Texas Texas 75270 EE. UU. | HRT FINANCEIRA LLC | 150 GREENWICH STREET (ATTENTION: AGREEMENT) FOUR WORLD TRADE CENTER PISO 57 NEW YORK NEW YORK 10007 EE. UU. | |
| HSBC BANK USA, NA/HSBC CUSTODY AND CLEARING SERVICES FOR STOCK LOANS | 452 FIFTH AVENUE CAUTION: HBUS CCS ASSEMBLIES NEW YORK NEW YORK 10018 EE. UU. | HSBC BANK USA, NATIONAL ASSOCIATION | 452 FIFTH AVENUE CAUTION: HBUS CCS ASSEMBLIES NEW YORK NEW YORK 10018 EE. UU. | |
| INTERACTIVE BROKERS LLC | 2 PLAZA PICKWICK 2° PISO GREENWICH Connecticut Connecticut 06830 EE. UU. | J.P. MORGAN CHASE BANK NA/FBO BLACKROCK CTF | 1111 POLARIS PARKWAY COLON OH OHIO 43240 | |
| J.P. MORGAN CLEARING CORP. | FOUR CHASE METROTECHNOLOGY CENTER 3rd WALK BROOKLYN NEW YORK 11201 EE. UU. | JANNEY MONTGOMERY SCOTT LLC | 1717 ARCH STREET PISO 17 PHILADELPHIA pennsylvania pennsylvania 19103 EE. UU. | |
| JEFFERIES LLC | 101 HUDSON STREET, 11th floor NEW JERSEY NJ NEW JERSEY 07302 EE. UU. | JPMORGAN CHASE BANK, NATIONAL ASSOCIATION | FOUR CHASE METROTECHNOLOGY CENTER 3rd WALK BROOKLYN NEW YORK 11201 EE. UU. | |
| JPMORGAN CHASE BANK/EUROCLEAR BANK | FOUR CHASE METROTECHNOLOGY CENTER 3rd WALK BROOKLYN NEW YORK 11245 EE. UU. | JPMORGAN CHASE BANK/IA | FOUR CHASE METROTECHNOLOGY CENTER 3rd WALK BROOKLYN NEW YORK 11201 EE. UU. | |
| NATIONAL ASSOCIATION OF THE MAIN BANKS | 4900 SCIENCE DR BROOKLYN OH OHIO 44144 EE. UU. | LAURENTIAN BANK VALORES INC. | 1981 MCGILL COLLEGE AVE. SUITE 100 MONTREAL QUEBEC H3A 3K3 CA CANADA | |
| LPL FINANCEIRA LLC | 4707 EXECUTIVE IMPULSE SAN DIEGO CA CALIFORNIA 92121EE. UU. | TRUSTED COMPANY BY MANUFACTURERS AND RESELLERS | A PLAZA M&T TRUST OPERATIONS 8TH FLOOR BUFFALO NEW YORK 14203 EE. UU. | |
| INCORPORATED MANULIFE VALUES | NORTHWEST SERVICE ROAD 1235 OAKVILLE IT'S ONTARIO L6M 2W2 CA CANADA | MARSCO INVESTMENT CORPORATION | ROAD EISENHOWER 101 ROSALANDIA NJ NEW JERSEY 07068 EE. UU. | |
| MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORADOS | 4804 Deer Lake Drive Este FL9-803-04-04- 4to piso JACKSONVILLE FL FLORIDA 32246 EE. UU. | INCREDIBLE ASSETS SECURITIES (USA) INC./SECURITIES LENDING CONDUCT ACCOUNT | 810 SEVENTH AVENUE PISO 37 NEW YORK NEW YORK 10019 | |
| WONDER ASSET SECURITIES (EE. UU.), INC. | 810 SEVENTH AVENUE PISO 37 NEW YORK NEW YORK 10019 | MITSUBISHI UFJ TRUST & BANKING CORPORATION, FILIAL DE NOVA YORK | 280 PARK AVENUE BUILDING 39TH FL-WEST NEW YORK NEW YORK 10017 | |
| Morgan Stanley | 1300 THAMES STREET THAMES STREET PIER BALTIMORE MD MARYLAND 21231 United States | MORGAN STANLEY & CO. LLC | 1300 THAMES ST. BALTIMORE MD MARYLAND | |
| MORGAN STANLEY SMITH BARNEY LLC | 1 NEW YORK SQUARE PISO 39 NEW YORK NEW YORK 10004 EE. UU. | MURIEL SIEBERT & CO., INC. | STREET OF SUMMER 77 3rd WALK BOSTON MA MASSACHUSETTS 02210 United States | |
| NATIONAL FINANCIAL SERVICES LLC | 499 BULEVAR WASHINGTON 5th WALK JERSEY CITY NJ NEW JERSEY 07310 United States | NBCN INC. | Rua De La Gauchetiere, 1010 Mezzanine 100 MONTREAL QUEBEC H3B 5J2 CA CANADA | |
| NOMURA'S TRUSTED INTERNATIONAL COMPANY | 309 WEST 49TH STREET PISO 10 NEW YORK NEW YORK 10019 E.E. UU. | LIMITED BROWN ODLUM | 250 CALLE HOWE SUITE 1100 VANCOUVER BC BRITISH COLUMBIA V6C 3R8 CA CANADA | |
| OPPENHEIMER & CO. INC. | 85 BROAD STREET NEW YORK NEW YORK 10004 EE. UU. | PERSHING LLC | 1 PLAZA PERSHING JERSEY CITY NJ NEW JERSEY 07399 EE. UU. | |
| PHILLIP CAPITAL INC. | 141 W. JACKSON BLVD. SUÍTE 3050 CHICAGO ILLINOIS 60604 EE. UU. | PI FINANCIAL CORPORATION. | 666 BURRARD ST SUITE 1900 VANCOUVER BC BRITISH COLUMBIA V6C 3N1 CA CANADA | |
| BANCO PNC, NATIONAL ASSOCIATION | WEST STREET 150 4100 3rd FL ASSET MOVEMENT TEAM, LOCATOR B7-YB17-03-03 CLEVELAND OH OHIO 44135 EE. UU. | MAIN BANK | RUA ALTA 711 MONGE A IOWA 50392 | |
| QUESTRADE INC./CDS** | 5650 YONGE ST., suite 1700 TORONTO IT'S ONTARIO M2M 4G3 CA CANADA | Raymond James & Associates, Inc. | 880 CARILLON PKWY S T. PETERSBURGO FL FLORIDA 33733-2749 EE. UU. | |
| RAYMOND JAMES LTDA. | 925 CALLE GEORGIA OCCIDENTAL SUITE 2200 VANCOUVER BC BRITISH COLUMBIA V6C 3L2 CA CANADA | RBC CAPITAL MARKETS, LLC | 60 ON CALL 6. MINNEAPOLIS Minnesota, Minnesota 55402 EE. UU. | |
| RBC DOMINION SECURITIES INC | 21 SOUTH COMMERCE COURT 2° PISO TORONTO IT'S ONTARIO M5L 1A7 CANADA | RELIABLE TRUSTWORTHY COMPANY | 1100 ABERNATHY RD. 500 NORTHPARK SUITE 400 ATLANTA GEORGIA 30113EE. UU. | |
| RELIABLE TRUSTWORTHY COMPANY | 4900 W. BROWN DEER RD MILWAUKEE WI WISCONSIN 53223EE. UU. | ROBERT W. BAIRD & CO. INCORPORADO | 777 E WISCONSIN AVE PISO 9 MILWAUKEE WI WISCONSIN 53202 EE. UU. | |
| ROBINHOOD SECURITIES, LLC | 500 COLONIAL CENTRO PARKWAY SUITE 100 LAKE MARY FL FLORIDA 32746 EE. UU. | SAFRA VALUES LLC | 546 5th AVENIDA NEW YORK NEW YORK 10036 EE. UU. | |
| SCOTIA CAPITAL (EE. UU.) INC. | 150 KING STREET W 5th WALK TORONTO IT'S ONTARIO M5H 1J9 CA CANADA | YOU ARE A PRIVATE TRUST COMPANY | 1 UNIT FREEDOM VALE ROBLES pennsylvania pennsylvania 19456 EE. UU. | |
| YOU ARE A PRIVATE TRUST COMPANY | 1 UNIT FREEDOM VALE ROBLES pennsylvania pennsylvania 19456 EE. UU. | SG AMERICAS SECURITIES, LLC | 480 WASHINGTON BLVD. PISO 20 JERSEY CITY NJ NEW JERSEY 07310 United States | |
| SSB - BLACKROCK INSTITUTIONAL TRUST | 50 California Street San Francisco CA CALIFORNIA 94163 | SSB - CUSTODY OF TRUST | 30 ADELAIDE ST IS SUITE 800 TORONTO IT'S ONTARIO M5C 3G6 CA CANADA | |
| SSB&T CO/CUSTOMER WARRANTY SERVICES | 1776 HERITAGE UNIT NORTH OF QUINCY MA MASSACHUSETTS 02171 | STATE STREET BANK E TRUST CO | 16 MURAL TWO 5th WALK NEW YORK NEW YORK 10005 EE. UU. | |
| STATE STREET BANK E TRUST COMPANY / ISHARES EUROPE | 1776 HERITAGE UNIT NORTH OF QUINCY MA MASSACHUSETTS 02171 | STATE STREET BANCO E TRUST / STATE STREET TOTAL | 1776 Heritage Drive NORTH OF QUINCY MA MASSACHUSETTS 02717 | |
| BANCO STATE STREET AND A TRUSTED COMPANY | 30 ADELAIDE ST IS SUITE 800 TORONTO IT'S ONTARIO M5C 3G6 CA CANADA | STIFEL, NICOLAUS & COMPANY, INCORPORATED | 501 N BROADWAY ST. T. LOUIS Measurements 63102 EE. UU. | |
| STONEX FINANCEIRA INC. | 2 SOUTH PERIMETRIAL PARK SUITE 100W BIRMINGHAM AL ALABAMA 35243 EE. UU. | TD AMERITRADE CLEARING, INC. | 200 S 108TH AVE OMAHA NE NEBRASKA 68154 EE. UU. | |
| TD WATERHOUSE CANADA INC ATTENTION: MANDATORY CORPORATE ACTIONS | 77 BLOOR WEST STREET 3rd WALK TORONTO IT'S ONTARIO M5S 1M2 CA CANADA | TEXAS TREASURY TRUST COMPANY | 208 E 10TH ST AUSTIN Texas Texas 78701 EE. UU. | |
| THE BANK OF NEW YORK MELLON | RUA GRANDE, 500 PISO 27 PITTSBURGH pennsylvania pennsylvania 15258 EE. UU. | HUNTINGTON NATIONAL BANK | 7 EASTON OVAL EA4E62 COLON OH OHIO 43209 EE. UU. | |
| THE NORTHERN TRUSTED COMPANY | 333 South Wabash Ave, piso 32 Attention: Processing of Commercial Securities CHICAGO ILLINOIS 60603 EE. UU. | TRADING STATION SECURITIES, INC. | 120 RIVERSIDE PLAZA SUITE 1650 CHICAGO ILLINOIS 60606 EE. UU. | |
| UNITED STATES BANCORP INVESTMENTS, INC. | 60 LIVINGSTON AVE EP-MN-WN1B SAO PAULO Minnesota, Minnesota 55107-1419 EE. UU. | BANK OF THE USA N.A./ETF | 1555N RIO CENTER DRIVE MILWAUKEE WI WISCONSIN 53212 | |
| NATIONAL ASSOCIATION OF US BANKS | 1555 NORTH RIVERCENTER DRIVE, SUITE 302 SUITE 302 MILWAUKEE WI WISCONSIN 53212 EE. UU. | UBS AG | 480 WASHINGTON BLVD. PISO 12 JERSEY CITY NJ NEW JERSEY 07310 United States | |
| UBS FINANCIAL SERVICES INC. | 1000 PORT BOULEVARD WEAHAWKEN NJ NEW JERSEY 07086 EE. UU. | UBS SECURITIES LLC | 677 WASHINGTON BLVD STAMFORD Connecticut Connecticut 06901 EE. UU. | |
| BANK UMB, NATIONAL ASSOCIATION | 928 GRAND BLVD KANSAS CITY Measurements 64106 EE. UU. | VANGUARD MARKETING CORPORATION | 100 VANGUARD BLVD MALVERN pennsylvania pennsylvania 19355 EE. UU. | |
| SPEED CLEANING, LLC | 1301 Ruta 36 Suite 109 (Attn: Chris Felicetti) HAZLET NEW JERSEY 7730 United States | VELOX CLEARING LLC | 2400 E. AVENIDA KATELLA SUITE 725A ANAHEIM CA CALIFORNIA 92806EE. UU. | |
| VIRTUE OF THE AMERICAS LLC | LIBERTY SQUARE, 165 BROADWAY 5th WALK NEW YORK NEW YORK 10006 EE. UU. | VISION FINANCIAL MARKETS LLC | 4 PARQUE HIGH RIDGE SUITE 100 STAMFORD Connecticut Connecticut 06905 EE. UU. | |
| WEDBUSH VALORES INC | 1000 WILSHIRE BLVD PISO 8 THE ANGELS CA CALIFORNIA 90017 E.E. UU. | WEDBUSH VALORES INC. | 1000 WILSHIRE BLVD. THE ANGELS CA CALIFORNIA 90017 E.E. UU. | |
| BANCO WELLS FARGO, NA/SIG | 733 MARQUETTE AVE 4TO PISO MAC N9306-04D MINNEAPOLIS Minnesota, Minnesota 55402 EE. UU. | WELLS FARGO CLEANING SERVICES LLC | 1 NORTH JEFFERSON MAIL CODE: H0006-094 ST. T. LOUIS Measurements 63103 EE. UU. | |
| WELLS FARGO VALUES, LLC | 1525 OESTE W T HARRIS BLVD CHARLOTTE north carolina north carolina 28262 United States | WILSON-DAVIS & CO., INC. | MAIN STREET 236 EM SALT LAKE CITY UT UTAH 84101 EE. UU. |
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. Sorrento's multimodal, multifaceted approach to fighting cancer is enabled by its broad immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors ("TKIs"), fully human antibodies ("G-MAB library ") ™ "). , immunocellular therapies ("DAR-T™"), antibody-drug conjugates ("ADC") and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™, and diagnostic test solutions including COVIMARK™.
Sorrento's commitment to life-enhancing therapies is also demonstrated by our effort to develop a TRPV1 agonist, a small molecule non-opioid pain control resiniferatoxin ("RTX") and SP-102 (10 mg, sodium phosphate dexamethasone viscous gel) (SEMDEXA™), a new viscous gel formulation of a corticosteroid widely used for epidural injections to treat lumbosacral radicular pain or sciatica, and to market 1.8% ZTlido® (topical lidocaine system) for the treatment of postherpetic neuralgia (PHN). RTX has been approved for a Phase II study for intractable cancer pain and a Phase II study in patients with osteoarthritis. Final positive results of Phase III C.L.E.A.R. The SEMDEXA™ program, its new non-opioid product for the treatment of lumbosacral radicular pain (sciatica), was announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit
Media and investor relations
Contato: Brian Cooley
E-mail:
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a registered trademark of Semnur Pharmaceuticals, Inc. Review of the proprietary name by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
©2023 Sorrento Therapeutics, Inc. All rights reserved.
